Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Eric Holmgren"'
Autor:
Zishuo Ian Hu, Johanna C. Bendell, Andrea Bullock, Noelle K. LoConte, Hassan Hatoum, Paul Ritch, Hugo Hool, Joseph W. Leach, James Sanchez, Davendra P. S. Sohal, John Strickler, Ravindranath Patel, Andrea Wang‐Gillam, Irfan Firdaus, Kenneth H. Yu, Ann M. Kapoun, Eric Holmgren, Lei Zhou, Jakob Dupont, Vincent Picozzi, Vaibhav Sahai, Eileen M. O'Reilly
Publikováno v:
Cancer Medicine, Vol 8, Iss 11, Pp 5148-5157 (2019)
Abstract Purpose Notch signaling dysregulation is implicated in the development of pancreatic adenocarcinoma (PDAC). Tarextumab is a fully human IgG2 antibody that inhibits Notch2/3 receptors. Patients and Methods Aphase 2, randomized, placebo‐cont
Externí odkaz:
https://doaj.org/article/65d331d0de7c4b2799fe21f23c85e265
Autor:
David H. Johnson, Roy S. Herbst, Corey J. Langer, Louis Fehrenbacher, William Novotny, Eric Holmgren, Jacques Gaudreault, John Nemunaitis, David M. Jablons, Fairooz F. Kabbinavar, Russell F. DeVore, Lisa A. Damico
Publikováno v:
Journal of Clinical Oncology. 41:2305-2312
Purpose To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. Patients and Methods In a phase II trial, 99 patients were randomly assigned to bevacizum
Autor:
Huiqiang Huang, Constantine S. Tam, Steven Le Gouill, Michael Wang, Stephen D. Smith, Alfredo Romano, Jane Huang, Eric Holmgren, Marco Ladetto, Martin Dreyling, William Novotny, Melannie Co
Publikováno v:
Future Oncology. 17:255-262
Mantle cell lymphoma is an aggressive B-cell malignancy. Current frontline chemoimmunotherapies produce high response rates but relapse is inevitable. Furthermore, the elderly and those with comorbidities are precluded from standard regimens and stem
Autor:
Kenneth H. Yu, James Sanchez, Jakob Dupont, Hassan Hatoum, Noelle K. LoConte, Eric Holmgren, Zishuo Ian Hu, Davendra Sohal, Paul S. Ritch, Andrea Wang-Gillam, John H. Strickler, Ravindranath Patel, Irfan Firdaus, Hugo Hool, Lei Zhou, Ann M. Kapoun, Andrea J. Bullock, Johanna C. Bendell, Eileen M. O'Reilly, Vaibhav Sahai, Joseph W. Leach, Vincent J. Picozzi
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 8, Iss 11, Pp 5148-5157 (2019)
Cancer Medicine, Vol 8, Iss 11, Pp 5148-5157 (2019)
Purpose Notch signaling dysregulation is implicated in the development of pancreatic adenocarcinoma (PDAC). Tarextumab is a fully human IgG2 antibody that inhibits Notch2/3 receptors. Patients and methods Aphase 2, randomized, placebo-controlled, mul
Autor:
Constantine S. Tam, William Novotny, Gavin Cull, Judith Trotman, Ziwen Tan, Siminder Kaur Atwal, Jane Huang, Eric Holmgren, Paula Marlton, David Gottlieb, Alessandra Tedeschi, David Simpson, James Hilger, Stephen Opat, Andrew W. Roberts, Javier Munoz, Yiling Yu, John F Seymour
Publikováno v:
Blood
Inhibitors of Bruton’s tyrosine kinase (BTK) have established therapeutic activity in patients with Waldenström macroglobulinemia (WM). Zanubrutinib, a potent and selective BTK inhibitor, was evaluated in a phase 1/2 study in patients with WM who
Autor:
Angelika Kühnle, Eric Holmgren, Ralf Bechstein, Peter Spijker, Ilka M. Hermes, Christoph Marutschke, Stefanie Klassen, John Tracey, Hagen Söngen, Adam S. Foster
Publikováno v:
Langmuir. 33:125-129
Solid-liquid interfaces are decisive for a wide range of natural and technological processes, including fields as diverse as geochemistry and environmental science as well as catalysis and corrosion protection. Dynamic atomic force microscopy nowaday
Autor:
Stephen Opat, Ziwen Tan, Alessandra Tedeschi, David Ritchie, Judith Trotman, Andrew W. Roberts, William Novotny, Jane Huang, David Simpson, Javier Munoz, Paula Marlton, John F. Seymour, Gavin Cull, Siminder Kaur Atwal, David Gottlieb, Emma Verner, Eric Holmgren, Constantine S. Tam
Publikováno v:
Journal of Clinical Oncology. 38:8051-8051
8051 Background: Inhibitors of Bruton tyrosine kinase (BTK) have established therapeutic activity in patients with WM. Zanubrutinib, a potent and selective BTK inhibitor was evaluated in a phase 1/2 study in treatment-naïve (TN) and relapsed/refract
Autor:
Huiqiang Huang, Constantine S. Tam, Jane Huang, Stephen D. Smith, Martin Dreyling, Michael Wang, Eric Holmgren, Melannie Co, Rebecca Elstrom, Steven Le Gouill, Marco Ladetto
Publikováno v:
Journal of Clinical Oncology. 38:TPS8071-TPS8071
TPS8071 Background: Bruton tyrosine kinase (BTK) mediates B-cell proliferation, migration, and adhesion. BTK inhibition has emerged as a strategy for targeting B-cell malignancies, including MCL. Zanubrutinib is a next-generation BTK inhibitor that w
Autor:
Eric Holmgren
Publikováno v:
Contemporary clinical trials. 63
Using stopping boundaries developed for group sequential trials, we control the overall type 1 error for a series of tests that evaluate the treatment effect of an experimental agent in each of several predefined marker subgroups. We then go on to pr
Autor:
Eric Holmgren
Publikováno v:
Statistics in Medicine. 27:4928-4938
This paper develops a framework for evaluating the usefulness of a PD biomarker as a primary endpoint in a Phase 2 screening trial of an oncology drug. We judge the contribution of the PD biomarker by assessing its impact on the efficiency of the dru